Number of arthritis patients in DANBIO and characteristics of RA patients at first registration according to ever and never treatment with TNF-I
| Ever treated with TNF-I* | Never-treated with TNF-I | |
|---|---|---|
| No of arthritis patients | ||
| All combined | 5345 | 4351 |
| RA | 3347 | 3812 |
| Ankylosing spondylitis | 861 | 136 |
| Psoriatic arthritis | 656 | 224 |
| Other arthritides | 481 | 179 |
| Characteristics of RA patients at start of follow-up | ||
| Mean age at start of follow-up, years (range) | 54.3 (15–87) | 61.2 (15–92) |
| Mean age at diagnosis, years | 44.9 | 51.8 |
| No of men (%) | 902 (27) | 998 (26) |
| Calendar year of inclusion | ||
| 2000–1 | 379 | 92 |
| 2002–3 | 561 | 46 |
| 2004–5 | 948 | 62 |
| 2006–7 | 1069 | 2807 |
| 2008 | 390 | 805 |
| No of IgM RF seropositive† (%) | 2411 (80) | 2593 (74) |
| Mean disease duration, years (range) | 10.7 (0–59) | 8.9 (0–68) |
| Proportion with disease duration <2 years | 18.7% | 31.6% |
| Mean no of tender joints of 28 count† (range) | 9.6 (0–28) | 4.1 (0–28) |
| Mean no of swollen joints of 28 count† (range) | 7.4 (0–28) | 2.8 (0–28) |
| Mean HAQ score† (range) | 1.3 (0–9.6) | 0.7 (0–3.0) |
| Mean CRP, mg/l† (range) | 27.0 (0–363) | 15.2 (0–232) |
| Mean DAS28† (range) | 5.1 (1.2–8.5) | 3.5 (1.0–8.4) |
*The number of rheumatoid arthriris (RA) patients ever treated with adalimumab was 1529 (46%), etanercept 1488 (44%) and infliximab 1617 (48%).
†Patients with missing values were not included. The percentage of patients with missing values was as follows (ever tumour necrosis factor α inhibitor (TNF-I) treated, never-treated): number of IgM rheumatoid factor (RF) seropositive (9.7%, 8.4%), number of tender joints (7.3%, 3.5%), number of swollen joints (5.7%, 3.3%), health assessment questionnaire (HAQ) score (18.1%, 16.6%), C-reactive protein (CRP) (6.4%, 12.3%), disease activity score in 28 joints (DAS28) (20.4%, 29.4%).